VHL-HIF-2α axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR-Reference-Cited by-同舟云学术

VHL-HIF-2α axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR

Published:2020-04-14 Issue:21 Volume:39 Page:4286-4298
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Liu Cheng^ORCID,Liu Li,Wang Kun,Li Xiao-Feng,Ge Li-Yuan,Ma Run-Zhuo,Fan Yi-Dong,Li Lu-Chao,Liu Zheng-Fang,Qiu Min,Hao Yi-Chang,Shi Zhen-Feng,Xia Chuan-You,Strååt Klas,Huang Yi,Ma Lu-Lin,Xu Dawei

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/s41388-020-1291-7.pdf

Reference48 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.

2. Hsieh JJ, Le VH, Oyama T, Ricketts CJ, Ho TH, Cheng EH. Chromosome 3p loss-orchestrated VHL, HIF, and epigenetic deregulation in clear cell renal cell carcinoma. J Clin Oncol. 2018;36:3533–9.

3. Chappell JC, Payne LB, Rathmell WK. Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers. J Clin Invest. 2019;129:442–51.

4. Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S, Chambers T, et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal. Cell. 2018;173:595–610 e511.

5. Minner S, Rump D, Tennstedt P, Simon R, Burandt E, Terracciano L, et al. Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. Cancer. 2012;118:1268–75.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of key genes and signalling pathways in clear cell renal cell carcinoma: An integrated bioinformatics approach;Cancer Biomarkers;2024-05-28

2. SMYD3 promotes endometrial cancer through epigenetic regulation of LIG4/XRCC4/XLF complex in non-homologous end joining repair;Oncogenesis;2024-01-08

3. Research Progress of Treatment of Renal Cell Carcinoma Based on Hypoxia Inducible Factor Pathway;Advances in Clinical Medicine;2024

4. Candidate biomarkers for treatment benefit from sunitinib in patients with advanced renal cell carcinoma using mass spectrometry-based (phospho)proteomics;Clinical Proteomics;2023-11-08

5. MFN2 suppresses clear cell renal cell carcinoma progression by modulating mitochondria‐dependent dephosphorylation of EGFR;Cancer Communications;2023-06-28